Seaport Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Seaport Therapeutics, Inc. (SPTX) had Debt Securities, Available-for-sale, Unrealized Loss Position of $800.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-03
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $800.00K.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $300.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $800.00K 10-Q · filed 2026-08-03 |
| 2026-03-31 | $300.00K 10-Q · filed 2026-06-08 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |